![]() |
![]() |
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
![]()
| Center | Date | Time | Location |
|---|---|---|---|
| CBER | March 15, 2005 | 8:30 a.m. - 5:40 p.m. | Holiday Inn Select
Bethesda |
Agenda:
The committee will review safety and immunogenicity for two Tetanus Toxoid,
Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Absorbed (Tdap) vaccines.
In the morning the committee will review safety and immunogenicity data for
Tdap vaccine manufactured by GlaxoSmithKline Biologicals. In the afternoon the
committee will review safety and immunogenicity data for Tdap vaccine manufactured
by Aventis Pasteur Ltd.
Background material and meeting information will become available no later than one business day before the meeting (Simply select the appropriate committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by March 8, 2005. Oral presentations from the public will be
scheduled between approximately 11:10 a.m. and 11:40 a.m. and approximately
4:10 p.m. and 4:40 p.m. Time allotted for each presentation may be limited.
Those desiring to make formal oral presentations should notify the contact person
before March 8, 2005, and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to make their
presentation. Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Christine Walsh or Denise Royster at least 7 days in advance
of the meeting.
Contact Person:
Christine Walsh or Denise Royster, Center for Biologics Evaluation
and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville,
MD. 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area), code 3014512391. Please call the
Information Line for up-to-date information on this meeting.
![]()